Vistagen Therapeutics (VTGN) Balance Sheet: Assets & Liabilities

Vistagen Therapeutics (VTGN) Balance Sheet

As of Mar 31, 2026 (end of fiscal 2026), Vistagen Therapeutics reported total assets of $48.56M and total liabilities of $13.04M. Shareholders' equity was $35.52M, down 49.5% from $70.39M a year earlier. Total debt stood at $345.00K against $45.40M in cash and short-term investments, a net cash position of $45.06M. That puts debt-to-equity at 0.01, compared with 0.02 a year earlier.

Vistagen Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Vistagen Therapeutics, Inc. (VTGN) - Annual data in millions USD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Current Assets
Cash and Cash Equivalents	30.79	67.13	119.17	16.64	68.14	103.11	1.36	13.10	10.38	2.92
Short-Term Investments	14.61	13.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	45.40	80.48	119.17	16.64	68.14	103.11	1.36	13.10	10.38	2.92
Accounts Receivable	0.00	0.00	0.00	0.80	2.75	0.04	0.00	0.30	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.00	0.00
Other Current Assets	1.54	1.59	1.51	0.07	0.07	1.01	0.23	0.25	0.64	0.46
Total Current Assets	46.94	82.08	120.67	17.51	71.00	104.12	1.58	13.65	11.02	3.38
Non-Current Assets
Property, Plant & Equipment (Net)	1.23	1.81	2.26	2.77	3.08	3.59	3.79	0.31	0.21	0.29
Other Non-Current Assets	0.39	0.45	0.73	0.82	0.57	0.58	0.40	0.05	0.05	0.05
Total Non-Current Assets	1.62	2.27	2.98	3.58	3.65	4.16	4.19	0.36	0.26	0.33
Total Assets	48.56	84.34	123.65	21.09	74.64	108.28	5.77	14.01	11.28	3.71
Current Liabilities
Accounts Payable	1.54	0.65	1.55	2.47	2.76	0.84	1.84	1.06	1.20	0.87
Short-Term Debt	0.10	0.56	0.55	0.59	0.43	0.37	0.37	0.06	0.06	0.06
Accrued Liabilities	8.43	8.81	0.62	0.80	1.26	1.56	-	-	-	-
Deferred Revenue	1.71	2.59	0.79	0.71	1.24	1.42	0.00	0.00	0.00	0.00
Other Current Liabilities	8.76	8.81	2.24	0.80	1.33	1.56	0.56	1.69	0.21	0.44
Total Current Liabilities	12.80	12.61	5.12	4.57	5.77	4.19	2.77	2.80	1.46	1.37
Non-Current Liabilities
Long-Term Debt	0.25	0.95	1.57	2.12	2.61	3.35	3.72	0.01	0.01	0.01
Other Non-Current Liabilities	0.00	0.39	2.67	0.00	0.00	8.76	5.01	4.13	2.89	1.72
Total Non-Current Liabilities	0.25	1.34	4.24	4.44	4.16	12.11	8.73	4.14	2.90	1.73
Total Liabilities	13.04	13.95	9.37	9.01	9.93	16.30	11.50	6.94	4.36	3.10
Stockholders' Equity
Common Stock	0.04	0.03	0.03	0.01	0.01	0.18	0.05	0.04	0.02	0.01
Retained Earnings	-477.32	-407.63	-356.21	-326.85	-267.60	-219.84	-201.91	-181.13	-156.54	-142.00
Accumulated Other Comprehensive Income	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Treasury Stock	3.97	3.97	3.97	3.97	3.97	-	-	-	-	-
Additional Paid-in Capital	516.77	481.96	474.44	338.93	336.28	311.64	196.12	188.16	163.43	142.60
Shares Outstanding	39.62	29.00	27.03	7.31	6.88	-	-	-	-	-
Total Stockholders' Equity	35.52	70.39	114.29	12.08	64.72	91.98	-5.73	7.08	6.92	0.62
Total Liabilities & Equity	48.56	84.34	123.65	21.09	74.64	108.28	5.77	14.01	11.28	3.71

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Vistagen Therapeutics Balance Sheet

How much debt does Vistagen Therapeutics have?

Vistagen Therapeutics had total debt of $345.00K as of Mar 31, 2026, against $45.40M in cash and short-term investments. Its debt-to-equity ratio was 0.01. Total debt was $1.51M a year earlier.

What are Vistagen Therapeutics's total assets?

Vistagen Therapeutics reported total assets of $48.56M as of Mar 31, 2026, down 42.4% from $84.34M a year earlier. Total liabilities were $13.04M.

What is Vistagen Therapeutics's shareholders' equity?

Vistagen Therapeutics's shareholders' equity was $35.52M as of Mar 31, 2026, or about $0.90 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition